Thrombophilia Panel 1
Uncover inherited clotting risks before they affect you.
The Thrombophilia Panel 1 is a genetic screening test designed for individuals with a personal or family history of abnormal blood clotting, recurrent pregnancy loss, or unexplained thrombosis. It helps identify inherited mutations that predispose to hypercoagulability, guiding clinical management and preventive strategies. Using PCR-hybridisation, this test analyses three key genetic variants associated with thrombophilia.
Genetic Variants Screened
- Factor II (G20210A): The prothrombin gene mutation, which increases prothrombin levels and raises the risk of venous thromboembolism.
- Factor V (Leiden G1691A): The Factor V Leiden mutation, which causes resistance to activated protein C and is a common inherited clotting disorder.
- MTHFR (C677T): The methylenetetrahydrofolate reductase mutation, which can lead to elevated homocysteine levels and a modestly increased clotting risk.
Why it matters
Identifying these mutations allows for personalised risk assessment, informed family planning, and targeted prophylaxis during high-risk situations such as surgery, pregnancy, or prolonged immobility. Early detection can prevent life-threatening thrombotic events and guide appropriate clinical surveillance.
Genetic Variants
- Factor II (G20210A)
- Factor V (Leiden G1691A)
- MTHFR (C677T)
Referral required
Important Clinical Information:
This test is a screening tool to monitor and support your overall health. It does not replace your GP or consultant.
Always discuss your test results, especially any abnormal results, with your GP, who can interpret them in the context of your medical history and overall health.